B
BioMimetic Therapeutics
Provider of orthopedic consultation and health care to patients
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. operated as a biotechnology firm focused on developing and commercializing drug-device combination products for musculoskeletal healing. The company was founded in 1999 by Dr. Samuel E. Lynch, a scientist and entrepreneur with doctorates from Harvard Medical School who pioneered research in regenerative medicine. Dr. Lynch identified the therapeutic potential of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) and led the company from its inception, through an initial public offering, to its eventual strategic sale.
The company's core business involved creating biologically active products to regenerate bone and associated tissues for orthopedic, spine, and sports injury applications. Its flagship product, Augment® Bone Graft, was developed as a synthetic alternative to autograft, the practice of harvesting a patient's own bone for grafting procedures. Augment combines rhPDGF-BB, which stimulates cell growth and proliferation, with a beta-tricalcium phosphate (β-TCP) scaffold that provides a framework for new bone formation. This approach was designed to offer comparable healing outcomes while eliminating the need for a second, often painful, surgery to harvest bone graft material. The company's business model relied on securing regulatory approvals and then marketing these products to surgeons and medical facilities. BioMimetic successfully gained marketing approval for Augment® in Canada, Australia, and New Zealand.
A significant milestone in the company's history was its acquisition by Wright Medical Group, Inc., an orthopedics company, in a deal announced in November 2012 and completed on March 1, 2013. The transaction was valued at a potential total of approximately $380 million, including an upfront payment of $190 million in cash and stock, plus additional milestone-based payments. The acquisition combined BioMimetic's biologics platform with Wright Medical's established sales force and extremities product portfolio, aiming to accelerate the market adoption of Augment®. Following the acquisition, the FDA approved Augment® Bone Graft in September 2015 for use in ankle and hindfoot fusion procedures. BioMimetic Therapeutics ceased to exist as an independent, publicly traded entity (NASDAQ: BMTI) and became a wholly owned subsidiary.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2012 | $190M | $190M | Wright Medical Group | — |
| EARLY VCOther financing | Jun 2009 | $2.9M | $12M | Undisclosed | — |
Growth signals
Latest recorded traffic for BioMimetic Therapeutics is 280 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BioMimetic Therapeutics in the Round Rock ecosystem
The BioMimetic Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Holden Capital
Burrill
Novo Holdings
MB Venture Partners
Series B and later6 investors entered at this stage
InterWest Partners
Mitsubishi
PTV Healthcare Capital
Noro-Moseley Partners- AVAxiom Ventures
Knowledge Ventures
Other known investors3 additional known investors
Harvard School of Dental Medicine
Harvard University
Wright Medical Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioMimetic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioMimetic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










